Shadi Baniasadi

Shadi Baniasadi

Auto-generated profile, based on publicly available information

Shadi Baniasadi

Tracheal Diseases Research Center, National Research institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
ARAndrea Rosanoff
Andrea Rosanoff
CWChristina West
Christina West
RERonald J. Elin
Ronald J. Elin
OMOliver Micke
Oliver Micke
SBShadi Baniasadi
Shadi Baniasadi
F(for the MaGNet Global Magnesium Project (MaGNet)
for the MaGNet Global Magnesium Project (MaGNet)

1 October 2010 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SBShadi Baniasadi
Shadi Baniasadi
PEParivash Eftekhari
Parivash Eftekhari
PTPayam Tabarsi
Payam Tabarsi
FFFanak Fahimi
Fanak Fahimi
MRMohammad Reza Raoufy
Mohammad Reza Raoufy
AVAli Akbar Velayati
Ali Akbar Velayati
Isoniazid, rifampicin, and pyrazinamide, the first-line antituberculosis (anti-TB) drugs, are associated with hepatotoxicity. To study the hepatoprotective effect of N-acetylcysteine (NAC) on liver injury induced by anti-TB drugs. A randomized clinical trial was conducted on 60 new TB patients who were aged 60 years or more. Patients were randomized into two groups. In group I (n=32), drug regimen included daily doses of isoniazid, rifampicin, pyrazinamide, and ethambutol. Patients in group II (n=28) were treated with the same regimen and NAC. The patients were followed up for 2 weeks. Liver enzymes and bilirubins were measured at baseline, after 1 and 2 weeks of treatment, and whenever the patients presented with clinical symptoms of hepatotoxicity. The mean+/-SD values of aspartate aminotransferase and alanine aminotransferase were significantly higher in group I than in group II after 1 and 2 weeks of treatment. Hepatotoxicity occurred in 12 patients with (37.5%) group I and none in group II. The mean duration of treatment before the onset of hepatotoxicity was 4.67+/-4.58 days. NAC protects against anti-TB drug-induced hepatotoxicity.

1 August 2002 in Neuroscience Letters
Verified
Journal Article
Closed access
ASAli mohammad Sharifi
Ali mohammad Sharifi
SBShadi Baniasadi
Shadi Baniasadi
MJMasoomeh Jorjani
Masoomeh Jorjani
FRFarzaneh Rahimi
Farzaneh Rahimi
MBMasoomeh Bakhshayesh
Masoomeh Bakhshayesh

13 March 2008 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
SBShadi Baniasadi
Shadi Baniasadi
FFFanak Fahimi
Fanak Fahimi
GSGloria Shalviri
Gloria Shalviri

1 January 2015 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
SBShadi Baniasadi
Shadi Baniasadi
BFBehrooz Farzanegan
Behrooz Farzanegan
MAMaryam Alehashem
Maryam Alehashem
Patients in the intensive care unit (ICU) are more prone to drug–drug interactions (DDIs). The software and charts that indicate all interactions may not be proper for clinical usage. This study aimed to identify the main drug classes associated with clinically significant DDIs in cardiothoracic ICU and categorize DDIs to make cardiothoracic intensivists aware of safe medication usage. This prospective study was conducted over 6 months in a cardiothoracic ICU of a university-affiliated teaching hospital. The presence of potential drug–drug interactions (pDDIs) was assessed by a clinical pharmacologist using Lexi-Interact database. Clinically significant pDDIs were defined according to severity and reliability rating. Interacting drug classes, mechanisms, and recommendations were identified for each interaction. From 1780 administered drugs, 496 lead to major (D) and contraindicated (X) interactions. Nine drug classes were responsible for D and/or X interactions with excellent (E) and/or good (G) reliability. Anti-infective agents (45.87 %) were the main drug classes that caused clinically significant pDDIs followed by central nervous system drugs (14.67 %). Azole antifungals as the most interacting antimicrobial agents precipitated metabolism inhibition of CYP3A substrates. Clinically significant pDDIs as potential patient safety risks were prevalent in critically ill patients. The findings from current study help to improve knowledge and awareness of clinicians in this area and minimize adverse events due to pDDIs.

18 May 2023 in Biology
Verified
Journal Article
Open access
PDF file
Fernando Guerrero-RomeroFernando Guerrero-Romero
Fernando Guerrero-Romero
OMOliver Micke
Oliver Micke
LSLuis E. Simental-Mendía
Luis E. Simental-Mendía
MRMartha Rodriguez-Moran
Martha Rodriguez-Moran
Juergen VormannJuergen Vormann
Juergen Vormann
MNMihai Nechifor
Mihai Nechifor
A large amount of published research points to the interesting concept (hypothesis) that magnesium (Mg) status may have relevance for the outcome of COVID-19 and that Mg could be protective during the COVID disease course. As an essential element, Mg plays basic biochemical, cellular, and physiological roles required for cardiovascular, immunological, respiratory, and neurological functions. Both low serum and dietary Mg have been associated with the severity of COVID-19 outcomes, including mortality; both are also associated with COVID-19 risk factors such as older age, obesity, type 2 diabetes, kidney disease, cardiovascular disease, hypertension, and asthma. In addition, populations with high rates of COVID-19 mortality and hospitalization tend to consume diets high in modern processed foods, which are generally low in Mg. In this review, we review the research to describe and consider the possible impact of Mg and Mg status on COVID-19 showing that (1) serum Mg between 2.19 and 2.26 mg/dL and dietary Mg intakes > 329 mg/day could be protective during the disease course and (2) inhaled Mg may improve oxygenation of hypoxic COVID-19 patients. In spite of such promise, oral Mg for COVID-19 has thus far been studied only in combination with other nutrients. Mg deficiency is involved in the occurrence and aggravation of neuropsychiatric complications of COVID-19, including memory loss, cognition, loss of taste and smell, ataxia, confusion, dizziness, and headache. Potential of zinc and/or Mg as useful for increasing drug therapy effectiveness or reducing adverse effect of anti-COVID-19 drugs is reviewed. Oral Mg trials of patients with COVID-19 are warranted.